Israel-based late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (Nasdaq: NRSN) announced on Tuesday that it has received a pivotal patent from the United States Patent and Trademark Office (USPTO) for the novel formulation of PrimeC, its leading drug candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Entitled 'Compositions comprising Ciprofloxacin and Celecoxib' (US Patent No. US 12,097,185), the newly granted patent is expected to extend PrimeC's patent protection by an additional four years, until 2042.
PrimeC includes ciprofloxacin and celecoxib, two FDA-approved compounds in unique doses, formulated in a technology of slow release to synchronise their pharmacokinetic (PK) profiles and enhance their therapeutic synergy. This approach is designed to optimise the treatment efficacy in slowing ALS progression.
Johnson & Johnson submits DARZALEX FASPRO supplemental Biologics License Application to FDA
Modalis Therapeutics receives FDA Rare Pediatric Disease designation for MDL-101 in LAMA2-CMD
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Astria Therapeutics secures FDA Orphan Drug Designation for Nnavenibart in HAE treatment
Bristol-Myers Squibb's schizophrenia drug Cobenfy receives US FDA approval
Pharming receives UK marketing authorisation for Joenja
DURECT Corporation announces design of upcoming registrational Phase 3 larsucosterol trial
EydisBio's EYD-001 receives US FDA Orphan Drug Designation
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
NeuroSense Therapeutics receives US patent for novel PrimeC formulation
IntraBio's Aqneursa receives US FDA approval
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Elevation Oncology's EO-3021 receives US FDA Fast Track designation
Lantern Pharma secures FDA designations for rare paediatric cancers